Braze (BRZE) reported strong Q2 results, beating revenue and EPS estimates, and raised Q3 and FY2027 guidance. Despite this, the stock fell significantly due to concerns over decelerating cRPO growth, which analysts largely dismiss as a short-term optical effect, maintaining positive ratings and price targets.
Braze (BRZE) announced upbeat fiscal second-quarter results, exceeding analyst expectations for revenue and earnings, and subsequently raised its guidance for the third quarter and full fiscal year 2027. Despite these strong fundamentals, the stock experienced a significant decline, which analysts attribute to a 'deceleration narrative' primarily driven by a perceived slowdown in current remaining performance obligation (cRPO) growth. Analysts from Stephens, Citizens JMP Securities, BTIG, and Needham largely view this as a short-term market overreaction or an optical effect, reiterating 'Buy' or 'Overweight' ratings and in some cases raising price targets. This presents a short-term opportunity for traders who believe the market is mispricing the stock based on strong underlying performance and long-term AI-driven growth potential, while the immediate risk is continued market skepticism regarding cRPO trends.